

Decreto Rettore Università di Roma “La Sapienza” n 162/2018 del 18/01/2018. Procedura valutativa di chiamata per n.1 posti di Professore di ruolo di II fascia per il settore concorsuale 06/N1 (SSD MED/46) presso il Dipartimento di Medicina Molecolare- Facoltà di Farmacia e Medicina

**Curriculum Vitae**  
**Alessandra SORIANI**

Rome, 14th February 2018

**Part I – General Information**

Full Name	<b>Alessandra Soriani</b>
Permanent Address	Department of Molecular Medicine, Sapienza University of Rome
Spoken Languages	English (written and oral): excellent

**Part II – Education**

Type	Year	Institution	Notes
University graduation	1996	University of Rome “La Sapienza”	Master Degree in Biology with full marks and honours
Licence in Biological Sciences	1997	University of Rome “La Sapienza”	
PhD	2003	University of Rome “La Sapienza”	PhD in Immunology
National Scientific qualification	validità abilitazione dal 09/06/2014 al 09/06/2020	University/MIUR	National Scientific qualification as associate in the sector 06/N1 (Applied medical technologies)

**Part III – Appointments**

**IIIA – Academic Appointments**

Start	End	Institution	Position
2008	at present	University of Rome “Sapienza”, Department of Molecular Medicine	University assistant professor in General Pathology (MED/04) (ricercatore universitario)
2005	2008	Dep. of Experimental Medicine and Pathology, University of Rome “La Sapienza”	Research fellow
2008	at present	“Sapienza” University of Rome	committee member for the evaluation of students (“commissioni d’esame di profitto”) ( <b>see Teaching Activities for a list of the Courses</b> )
2011	2017	“Sapienza” University of Rome	member of the teaching body for the evaluation of PhD students (PhD school in Immunological, Hematological and Rheumatological Sciences)

2017	at present	“Sapienza” University of Rome	member of the teaching body for the evaluation of PhD students (PhD school in “Innovation in immune-mediated and hematological disorders”
2017	at present	“Sapienza” University of Rome	chairman of the Bachelor in “Terapia della Neuro e Psicomotricità età evolutiva "B" in Professioni Sanitarie della Riabilitazione”- Faculty of Pharmacy and Medicine – Sapienza University of Rome

### IIIB – Other Appointments

Start	End	Institution	Position
2003	2004	Department of Cell Biology, The SCRIPPS Research Institute, La Jolla, California, USA.	research associate
2004	2005	Department of Medicine, University City of San Diego, San Diego, California, USA.	research associate

### Part IV – Teaching experience

Year	Institution	Lecture/Course
A.Y. 2008/2009 at present	“Sapienza” University of Rome	Course in <i>General Pathology</i> - Faculty of Pharmacy and Medicine, degree in “Terapia della Neuro e Psicomotricità età evolutiva "B" in Professioni Sanitarie della Riabilitazione”
A.Y. 2011/2012	“Sapienza” University of Rome	Course in Clinical Pathology - degree in “Terapia della Neuro e Psicomotricità età evolutiva "B" in Professioni Sanitarie della Riabilitazione”
A.Y. 2015/2016 at present	“Sapienza” University of Rome	Course in General Pathology- Faculty of Medicine and Dentistry, degree in “Tecniche di fisiopatologia cardiocircolatoria e perfusione cardiovascolare”
A.Y 2017/2018	“Sapienza” University of Rome	Course in General Physiopathology- Faculty of Medicine and Psychology, degree in “Infermieristica” (abilitante alla professione sanitaria di Infermiere) ROMA - A.O. S. Camillo L/SNT1
A.Y. 2008/2009 at present	“Sapienza” University of Rome	Supervision and tutorship of several university and PhD students

### Part V - Society memberships, Awards and Honors

Year	Title
since 2008	Member of the Italian Society of Immunology, Clinical Immunology and Allergology (SIICA)
2011	2011 Joint SIICA-DGFI Best Abstract Awards
2003	FIRC (Fondazione Italiana per la Ricerca sul cancro) Fellowship

### Part VI - Funding Information [grants as PI-principal investigator or I-investigator

Year	Title	Program	Grant Value
2009	Analisi del ruolo dello stress ossidativo nel controllo dell'espressione dei ligandi dei recettori attivatori NK in cellule di mieloma trattate con farmaci chemioterapia (PI)	Sapienza University of Rome/ Ricerche di Ateneo Federato	900Euro
2010	Endocitosi del recettore attivatorio NKG2D e dei suoi ligandi: implicazioni nella regolazione della risposta immunitaria adattativa (PI)	Sapienza University of Rome/ Ricerca Scientifica	13500Euro
2012	La trasduzione del segnale dei recettori chemochinici in condizioni fisiologiche e patologiche: basi molecolari per lo sviluppo di nuove terapie (PI)	FIRB-MIUR	212000 Euro
2014	Molecular mechanisms involved in NKG2D and DNAM-1 activating ligand regulation in human CMV-infected cells (PI)	"Sapienza" University of Rome/ Ricerca Scientifica	3000 Euro + 23075,04 Euro per assegno di ricerca
2016	Paracrine effect of drug-dependent secretome on neighboring non-senescent tumor cells (PI)	"Sapienza" University of Rome/ Ricerca Scientifica	14000 Euro
2007	Effector functions of distinct NK cell subsets in tumor microenvironment: molecular mechanisms (I)	AIRC	555.000Euro
2010	Molecular events regulating anti-cancer NK cell mediated stress surveillance response induced by chemotherapy (I)	AIRC	540.000Euro
2014	Role of BM microenvironment in shaping NK cell maturation and effector functions in Multiple Myeloma (I)	AIRC	420.000Euro
2017	Molecular events regulating NK cell functional maturation and trafficking capacity in WHIM syndrome	"Sapienza" University of Rome/ Ricerca Scientifica	34500 Euro

## Part VII – Research Activities

Keywords	Brief Description
Innate Immunity; NK cells; integrins	<b>1998-2002:</b> study of the role of integrins in the NK cell function regulation. My main interest has been focused on understanding the role of the intracellular signaling pathways triggered by several surface activation/adhesion receptors in NK cell functions. We have first demonstrated that integrins behave as signaling receptors in NK cells. All these results have been conducted in the laboratory of Prof. Santoni and published in highly qualified international journals.
platelets, inside-out and outside-in signaling	<b>2003-2005:</b> analysis of activation phenomenon and intracellular signaling of human $\alpha$ IIb $\beta$ 3 integrin in human platelets. In particular, I have focused my attention to the molecular interaction between integrin adhesion receptors and protein kinases C (PKCs) relevant to cancer progression and metastasis. The research activity was conducted in the Laboratory of Prof. Shattil, at The SCRIPPS and UCSD, San Diego, Ca. My research has been published in highly qualified international journals.

Immuno-surveillance, chemotherapies	<p><b>2006-to date:</b> Role of NK cells in the control of Multiple Myeloma progression. In these years I have provided new insights on the immuno-mediated antitumor activities of several chemotherapeutic agents, that work through the modulation of the balance between activating and inhibitory NK cell signals resulting in enhanced sensitization of cancer cells to NK cell-mediated cytotoxicity. In particular, I have demonstrated that genotoxic drugs including doxorubicin and melphalan by generating reactive oxygen species induce a DNA Damage Response-dependent increase of activating NK receptor ligand expression on senescent tumor cells. More recently, I have also proven that expression of the NKG2D and DNAM-1 activating ligands is enhanced by immunomodulatory drugs (IMiDs) and tubulin polymerization inhibitors such as Vincristine. Altogether, my studies unravel different mechanisms underlying the immunomodulatory effects of chemotherapies, in particular their impact on the NK-cell effector response. This research has been published in highly qualified international journals.</p> <p>More recently, I started a project that propose to bridge the gap between <i>in vitro</i> and <i>in vivo</i> experimentation by employing a bio-printed 3D platform to mimic Multiple Myeloma tumor microenvironment.</p>
-------------------------------------	--

### Part VIII – Summary of Scientific Achievements

Product type	Number	Data Base	Start	End
Papers [international]	41	SCOPUS (www.scopus.com)	1998	2018
Papers [national]	-		-	-
Books [scientific]	-		-	-
Books [teaching]	-		-	-

Total Impact factor (year of publication)	246,66
Average Impact factor	6,02
Total Impact factor per publication (calculated in accordance to the year of publication)	251,91
Average Impact factor per publication (calculated in accordance to the year of publication)	6,14
10 years Impact Factor	174,92
10 years Impact Factor per publication (calculated in accordance to the year of publication)	183,54
Number of publications (Scopus)	41
Total Citations (Scopus)	1441
Average Citations per Product	35.14
Hirsch (H) index (Scopus)	18
Normalized H index*	0,85

\*H index divided by the academic seniority.

### Part IX– Selected Publications (Data base: SCOPUS)

- 1- Fionda C, Malgarini G, Soriani A, Zingoni A, Cecere F, Iannitto ML, Ricciardi MR, Federico V, Petrucci MT, Santoni A, Cippitelli M. Inhibition of glycogen synthase kinase-3 increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of STAT3. *J Immunol.* 2013 Jun 15;190(12):6662-72. doi: 10.4049/jimmunol.1201426. Epub 2013 May 17 **IF:5.362 citations:32**
- 2- Soriani A, Fionda C, Ricci B, Iannitto ML, Cippitelli M, Santoni A. Chemotherapy-elicited upregulation of NKG2D and DNAM-1 ligands as a therapeutic target in multiple myeloma. *Oncoimmunology.* 2013 Dec 1;2(12):e26663. Epub 2013 Oct 22. Review. **IF:6.283 citations:13**
- 3- Soriani A, Iannitto ML, Ricci B, Fionda C, Malgarini G, Morrone S, Peruzzi G, Ricciardi MR, Petrucci MT, Cippitelli M, Santoni A. Reactive Oxygen Species- and DNA Damage Response-Dependent NK Cell Activating Ligand Upregulation Occurs at Transcriptional Levels and Requires the Transcriptional Factor E2F1. *J Immunol.* 2014 Jul 15;193(2):950-60. doi: 10.4049/jimmunol.1400271. Epub 2014 Jun 9. **IF:4.922 citations:31**

4- Petroni M, Sardina F, Heil C, Sahún-Roncero M, Colicchia V, Veschi V, Albini S, Fruci D, Ricci B, Soriani A, Di Marcotullio L, Screpanti I, Gulino A, Giannini G. The MRN complex is transcriptionally regulated by MYCN during neural cell proliferation to control replication stress. *Cell Death Differ.* 2016 Feb;23(2):197-206. doi: 10.1038/cdd.2015.81. Epub 2015 Jun 12. **IF:8.218 citations:5**

5- Zingoni A, Cecere F, Vulpis E, Fionda C, Molfetta R, Soriani A, Petrucci MT, Ricciardi MR, Fuerst D, Amendola MG, Mytilineos J, Cerboni C, Paolini R, Cippitelli M, Santoni A. Genotoxic Stress Induces Senescence-Associated ADAM10-Dependent Release of NKG2D MIC Ligands in Multiple Myeloma Cells. *J Immunol.* 2015 Jul 15;195(2):736-48. doi: 10.4049/jimmunol.1402643. Epub 2015 Jun 12. **IF:4.985 citations:16**

6- La Regina G, Bai R, Coluccia A, Famigliani V, Pelliccia S, Passacantilli S, Mazzoccoli C, Ruggieri V, Verrico A, Miele A, Monti L, Nalli M, Alfonsi R, Di Marcotullio L, Gulino A, Ricci B, Soriani A, Santoni A, Caraglia M, Porto S, Da Pozzo E, Martini C, Brancale A, Marinelli L, Novellino E, Vultaggio S, Varasi M, Mercurio C, Bigogno C, Dondio GM, Hamel E, Lavia P, Silvestri R. New Indole Tubulin Assembly Inhibitors Cause Stable Arrest of Mitotic Progression, Enhanced Stimulation of Natural Killer Cell Cytotoxic Activity and Repression of Hedgehog-dependent Cancer. *J Med Chem.* 2015 Aug 13;58(15):5789-807. doi: 10.1021/acs.jmedchem.5b00310. Epub 2015 Jul 20. **IF:5.589 citations:14**

7- Dupuis ML\*, Fiori V\*, Soriani A\*, Ricci B, Moricoli D, Dominici S, Ascione A, Santoni A, Magnani M and Cianfriglia M. \*equally contributed to the work. The Human Antibody Fragment DIATHIS1 Specific for CEACAM1 Enhances Natural Killer-Cell Cytotoxicity Against Melanoma Cell Lines in vitro. *J Immunother.* 2015 Nov-Dec;38(9):357-70. doi: 10.1097/CJI.000000000000100. **IF:3.712 citations:5**

8- Antonangeli F, Soriani A, Ricci B, Ponzetta A, Benigni G, Morrone S, Bernardini G, Santoni A. Natural Killer cell recognition of in vivo drug-induced senescent Multiple Myeloma cells. *Oncoimmunology.* 2016, 5(10):e1218105. eCollection 2016. **IF: 7.719 citations: 4**

9- Soriani A, Borrelli C, Ricci B, Molfetta R, Zingoni A, Fionda C, Carnevale S, Abruzzese MP, Petrucci MT, Ricciardi MR, La Regina G, Di Cesare E, Lavia P, Silvestri R, Paolini R, Cippitelli M, Santoni A. p38 MAPK differentially controls NK activating ligands at transcriptional and post-transcriptional level on multiple myeloma cells. *Oncoimmunology.* 2017, 6(1):e1264564. doi: 10.1080/2162402X.2016.1264564. eCollection 2017. (IF del 2016) **IF:7.719 citations:6**

10- Vulpis E, Cecere F, Molfetta R, Soriani A, Fionda C, Peruzzi G, Caracciolo G, Palchetti S, Masuelli L, Simonelli L, D'Oro U, Abruzzese MP, Petrucci MT, Maria Rosaria Ricciardi MR, Paolini R, Cippitelli M, Santoni A, Zingoni A. Genotoxic stress increases exosome release from multiple myeloma cells with a stimulatory effect on NK cells: role of TLR2/Hsp70/NF-kB axis. *Oncoimmunology.* 2017, 6(3):e1279372. doi: 10.1080/2162402X.2017.1279372. eCollection 2017. (IF del 2016) **IF:7.719 citations:2**

11- Abruzzese MP, Bilotta MT, Fionda C, Zingoni A, Soriani A, Vulpis E, Borrelli C, Zitti B, Petrucci MT, Ricciardi MR, Molfetta R, Paolini R, Santoni A, Cippitelli M. Inhibition of Bromodomain and Extra-Terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in Multiple Myeloma cells: role of cMYC-IRF4-miR-125b interplay. *J Hematol Oncol.* 2016 Dec 1;9(1):134. **IF:6.35 citations:7**

12-Zingoni A, Fionda C, Borrelli C, Cippitelli M, Santoni A, Soriani A. Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance. *Front Immunol.* 2017 Sep 25;8:1194. doi: 10.3389/fimmu.2017.01194. eCollection 2017. Review. **IF:6.429 citations:1**

## Part X– Total Publications

1-Mainiero F., Gismondi A., Soriani A., Cippitelli M., Palmieri G., Jacobelli J., Piccoli M., Frati L. and Santoni A. Integrin-mediated Ras-Extracellular Regulated Kinase (ERK) signaling regulates interferon  $\gamma$  production in human natural killer cells. *J. Exp. Med.*188(7):1267-1275, 1998. IF:15.882

2-Mainiero F., Soriani A., Strippoli R., Jacobelli J., Gismondi A., Piccoli M., Frati L. and Santoni A. Rac1/p38 MAPK signaling pathway controls  $\beta$ 1  $\alpha$ 1 integrin-induced interleukin-8 production in human natural killer cells. *Immunity* 12:7-16, 2000. IF:21.083

3-Mainiero F., Gismondi A., Strippoli R., Jacobelli J., Soriani A., Morrone S., Santoni A. Integrin-mediated regulation of cytokine and chemokine production by human NK cells. *European Cytokine Network* 11:493-494, 2000. IF:1.693

4-Mainiero F., Gismondi A., Strippoli R., Soriani A., Jacobelli J., Santoni A. Integrine e Cellule Natural Killer. *EOS-Journal of Immunology and Immunopharmacology* 20 (3):63-68, 2000.

5-Giovanni F. Torelli, R. Paolini, C. Tatarelli, A. Soriani, A. Vitale, A. Guarini, A. Santoni and R. Foa. Defective Expression of the T-Cell Receptor-CD3 Zeta Chain in T Acute Lymphoblastic Leukaemia. *British Journal of Haematology* 120 (2):201-8, 2003. IF:3.267

- 6**-Gismondi A., Jacobelli J., Strippoli R., Mainiero F., Soriani A, Cifaldi L., Piccoli M., Frati L. and Santoni A. Pyk-2 and Rac activation by chemokine and integrin receptors control NK cell transendothelial migration. *J. Immunol.* 170 (6):3065-73, 2003. IF:6.702
- 7**-Uccini S., Scarpino S., Ballarini F., Soriani A., Chilosi M., Montesu M.A., Masala M.V., Cottoni F., Ruco L. In situ study of chemokine and chemokine-receptor expression in kaposi sarcoma. *Am. J. Dermatopathol.* 25(5):377-83, 2003. IF:1.132
- 8**-Buensuceso C.S., Obergfell A., Soriani A., Eto K., Kiosses W.B., Arias-Salgado E.G., Kawakami T., Shattil S.J. Regulation of outside-in signaling in platelets by integrin-associated protein kinase Cbeta. *J. Biol. Chem.* 280(1):644-53, 2005. IF:5.854
- 9**-Soriani A., Moran B., de Virgilio M., Kawakami Y., Altman A., Lowell C., Eto K., and Shattil S.J. A role for PKCtheta in outside-in alphallbbeta3 signaling. *J Thromb Haemost.* 4 (3):648-55, 2006. IF:5.138
- 10**-Han J., Lim C.J., Watanabe N., Soriani A., Ratnikov B., Calderwood D.A., Puzon-McLaughlin, Lafuente E.M., Boussiotis V.A., Shattil S.J., Ginsberg M.H. Reconstructing and deconstructing agonist-induced activation of integrin allbb3 (platelet GpIIb-IIIa). *Curr. Biology* 16(18):1796-806, 2006. IF:10.988
- 11**-Carlino C., Stabile H., Morrone S., Bulla R., Soriani A., Agostinis C., Bossi F., Mocci C., Sarazani F., Tedesco F., Santoni A., Gismondi A. Recruitment of circulating NK cells through decidual tissues: a possible mechanism controlling NK cell accumulation in the uterus during early pregnancy. *Blood* 111 (6):3108-15, 2008. IF:10.432
- 12**-Soriani A., Zingoni A., Cerboni C., Iannitto M. L., Ricciardi M. R., Di Gialleonardo V., Cippitelli M., Fionda C., Petrucci M.T., Guarini A., Foà A., and Santoni A. ATM-ATR dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK cell susceptibility and is associated with a senescent phenotype. *Blood* 113 (15):3503-11, 2009. IF:10.555
- 13**-Fionda C., Soriani A., Malgarini G., Iannitto M.L., Cippitelli M., and Santoni A. Hsp90 inhibitors increase MHC Class I-Related Chain A and B ligands and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cell lines. *J.Immunol.*183 (7):4385-94, 2009. IF:5.646
- 14**-Sciumè G., Soriani A., Piccoli M., Frati L., Santoni A., and Bernardini G. CX3CR1/CX3CL1 axis negatively controls glioma cell invasion and is modulated by transforming growth factor-beta1. *Neuro Oncol.* 12(7):701-10, 2010. IF:5.483
- 15**-Ardolino M., Zingoni A., Cerboni C. Cecere F., Soriani A., Iannitto ML., and Santoni A. The expression of the DNAM-1 ligands on Ag-stimulated T lymphocytes is mediated by ROS-dependent activation of DNA-damage Response: relevance for NK-T cell interaction. *Blood.* 117(18):4778-86, 2011. IF:9.898
- 16**-Silvestri R., La Regina G., Bai R., Rensen W., Coluccia A., Piscitelli F., Gatti V., Bolognesi A., Lavecchia A., Granata I., Porta A., Maresca B., Soriani A., Iannitto M.L., Mariani M., Santoni A., Brancale A., Ferlini C., Dondio M.G., Varasi M., Mercurio C., Hamel E., Lavia P., Novellino E. Design and Synthesis of 2-Heterocyclyl-3-arylthio-1H-indoles as Potent Tubulin Polymerization and Cell Growth Inhibitors with Improved Metabolic Stability. *J Med Chem.* 54(24):8394-406, 2011. IF:5.248
- 17**-Quinci A., Vitale S., Parretta E., Soriani A., Iannitto M.L., Cippitelli M., Fionda C., Bulfone-Paus S., Santoni A., Di Rosa F. IL-15-induced inhibition of IL-7 receptor expression by memory-phenotype CD8 T cells in the bone marrow. *Eur J Immunol*, 42(5):1129-39, 2012. IF:4.970
- 18**-Carlino C., Trotta E., Stabile H., Morrone S., Bulla R., Soriani A., Iannitto M.L., Agostinis C., Mocci C., Minozzi M., Aragona C., Perniola G., Tedesco F., Sozzani S., Santoni A. and Gismondi A. Chemerin regulates NK cell accumulation and endothelial cell morphogenesis in the decidua during early pregnancy. *The Journal of Clinical Endocrinology & Metabolism*, 97(10):3603-12, 2012. IF: 6.430
- 19**- La Regina G., Bai R., Whilelmina Rensen W.M., Di Cesare E., Coluccia A., Piscitelli F., Famigliani V., Reggio A., Nalli M., Pelliccia S., Da Pozzo E., Costa B., Granata I., Porta A, Maresca B., Soriani A., Iannitto M.L., Santoni A., Li J., Cona M.M., Chen F., Ni Y., Brancale A., Dondio G., Vultaggio S., Varasi M., Mercurio C., Martini C., Hamel E., Lavia P., Novellino E., and Silvestri R. Toward highly potent cancer agents by modulating the C-2 group of the arylthioindole class of tubulin polymerization inhibitors. *J Med Chem.* 56(1):123-49, 2013. IF:5.480
- 20**- Fionda C, Malgarini G, Soriani A, Zingoni A, Cecere F, Iannitto ML, Ricciardi MR, Federico V, Petrucci MT, Santoni A, Cippitelli M. Inhibition of glycogen synthase kinase-3 increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of STAT3. *J Immunol.*190(12):6662-72, 2013. IF:5.362
- 21**- Soriani A, Fionda C, Ricci B, Iannitto ML, Cippitelli M, Santoni A. Chemotherapy-elicited upregulation of NKG2D and DNAM-1 ligands as a therapeutic target in multiple myeloma. *Oncolmmunology.* 2(12):e266632013, 2013. IF:6.283
- 22**- Cerboni C, Fionda C, Soriani A, Zingoni A, Doria M, Cippitelli M, Santoni A. The DNA Damage Response: A Common Pathway in the Regulation of NKG2D and DNAM-1 Ligand Expression in Normal, Infected, and Cancer Cells. *Front Immunol.* 4:508,2014. IF:6.429

- 23-** Soriani A, Iannitto ML, Ricci B, Fionda C, Malgarini G, Morrone S, Peruzzi G, Ricciardi MR, Petrucci MT, Cippitelli M, Santoni A. Reactive Oxygen Species- and DNA Damage Response-Dependent NK Cell Activating Ligand Upregulation Occurs at Transcriptional Levels and Requires the Transcriptional Factor E2F1. *J Immunol*. 2014 Jun 9. pii: 1400271. IF:4.922
- 24-** Fionda C, Abruzzese M, Zingoni A, Soriani A, Ricci B, Molfetta R, Paolini R, Santoni A, Cippitelli M. Nitric oxide donors increase PVR/CD155 DNAM-1 ligand expression in multiple myeloma cells: role of DNA damage response activation. *BMC Cancer*. 2015 Jan 22;15(1):17. IF:3.265
- 25-** Amantini C, Morelli MB, Santoni M, Soriani A, Cardinali C, Farfariello V, Eleuteri AM, Bonfili L, Mozzicafreddo M, Nabissi M, Cascinu S, Santoni G. Sorafenib induces cathepsin B-mediated apoptosis of bladder cancer cells by regulating the Akt/PTEN pathway. The Akt inhibitor, perifosine, enhances the sorafenib-induced cytotoxicity against bladder cancer cells. *Oncoscience*. 2015 Mar 23;2(4):395-409.
- 26-** Petroni M, Sardina F, Heil C, Sahún-Roncero M, Colicchia V, Veschi V, Albini S, Fruci D, Ricci B, Soriani A, Di Marcotullio L, Screpanti I, Gulino A, Giannini G. The MRN complex is transcriptionally regulated by MYCN during neural cell proliferation to control replication stress. *Cell Death Differ*. 2015 Jun 12. doi: 10.1038/cdd.2015.81. IF:8.218
- 27-** Zingoni A, Cecere F, Vulpis E, Fionda C, Molfetta R, Soriani A, Petrucci MT, Ricciardi MR, Fuerst D, Amendola MG, Mytilineos J, Cerboni C, Paolini R, Cippitelli M, Santoni A. Genotoxic Stress Induces Senescence-Associated ADAM10-Dependent Release of NKG2D MIC Ligands in Multiple Myeloma Cells. *J Immunol*. 2015 Jun 12. pii: 1402643. IF:4.985
- 28-** La Regina G, Bai R, Coluccia A, Famigliani V, Pelliccia S, Passacantilli S, Mazzoccoli C, Ruggieri V, Verrico A, Miele A, Monti L, Nalli M, Alfonsi R, Di Marcotullio L, Gulino A, Ricci B, Soriani A, Santoni A, Caraglia M, Porto S, Da Pozzo E, Martini C, Brancale A, Marinelli L, Novellino E, Vultaggio S, Varasi M, Mercurio C, Bigogno C, Dondio GM, Hamel E, Lavia P, Silvestri R. New Indole Tubulin Assembly Inhibitors Cause Stable Arrest of Mitotic Progression, Enhanced Stimulation of Natural Killer Cell Cytotoxic Activity and Repression of Hedgehog-dependent Cancer. *J Med Chem*. 2015 Jul 1. IF:5.589
- 29-** Fionda C, Soriani A, Zingoni A, Santoni A, Cippitelli M. NKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple Myeloma. *Biomed Res Int*. 2015;2015:178698. Epub 2015 Jun 16. Review. IF:2.134
- 30-** Dupuis ML\*, Fiori V\*, Soriani A\*, Ricci B, Moricoli D, Dominici S, Ascione A, Santoni A, Magnani M and Cianfriglia M. The Human Antibody Fragment DIATHIS1 Specific for CEACAM1 Enhances Natural Killer-Cell Cytotoxicity Against Melanoma Cell Lines *in vitro*. *\*these authors equally contributed to the manuscript*. *Journal of Immunotherapy*, 38(9), 2015. IF:3.712
- 31-** Morelli MB, Amantini C, Santoni M, Soriani A, Nabissi M, Cardinali C, Santoni A, Santoni G. Axitinib induces DNA damage response leading to senescence, mitotic catastrophe, and increased NK cell recognition in human renal carcinoma cells. *Oncotarget*. 2015 Oct 14. doi: 10.18632/oncotarget.5768. IF:5.008
- 32-** Fionda C, Abruzzese MP, Zingoni A, Cecere F, Vulpis E, Peruzzi G, Soriani A, Molfetta R, Paolini R, Ricciardi MR, Petrucci MT, Santoni A, Cippitelli M. The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma. *Oncotarget*. 2015 Sep 15;6(27):23609-30. IF: 5.008
- 33-** Antonangeli F, Soriani A, Ricci B, Ponzetta A, Benigni G, Morrone S, Bernardini G, Santoni A. Natural Killer cell recognition of in vivo drug-induced senescent Multiple Myeloma cells. *Oncoimmunology*. 2016 Aug 5;5(10):e1218105. IF: 7.719
- 34-** Nabissi M, Morelli MB, Offidani M, Amantini C, Gentili S, Soriani A, Cardinali C, Leoni P, Santoni G. Cannabinoids synergize with carfilzomib, reducing multiple myeloma cells viability and migration. *Oncotarget*. 2016 Oct 18. doi: 10.18632/oncotarget.12721. IF:5.168
- 35-** Soriani A, Borrelli C, Ricci B, Molfetta R, Zingoni A, Fionda C, Carnevale S, Abruzzese MP, Petrucci MT, Ricciardi MR, La Regina G, Di Cesare E, Lavia P, Silvestri R, Paolini R, Cippitelli M, Santoni A. p38 MAPK differentially controls NK activating ligands at transcriptional and post-transcriptional level on multiple myeloma cells. *Oncoimmunology*. 2016 Dec 2;6(1):e1264564. IF:7.719
- 36-** Vulpis E, Cecere F, Molfetta R, Soriani A, Fionda C, Peruzzi G, Caracciolo G, Palchetti S, Masuelli L, Simonelli L, D'Oro U, Abruzzese MP, Petrucci MT, Maria Rosaria Ricciardi MR, Paolini R, Cippitelli M, Santoni A, Zingoni A. Genotoxic stress increases exosome release from multiple myeloma cells with a stimulatory effect on NK cells: role of TLR2/Hsp70/NF- $\kappa$ B axis. *Oncoimmunology*. 2016 IF:7.719
- 37-** Abruzzese MP, Bilotta MT, Fionda C, Zingoni A, Soriani A, Vulpis E, Borrelli C, Zitti B, Petrucci MT, Ricciardi MR, Molfetta R, Paolini R, Santoni A, Cippitelli M. Inhibition of Bromodomain and Extra-Terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in Multiple Myeloma cells: role of cMYC-IRF4-miR-125b interplay. *J Hematol Oncol*. 2016 Dec 1;9(1):134. IF:6.35
- 38-** Barroeta Seijas AB, Simonetti S, Vitale S, Runci D, Quincu AC, Soriani A, Criscuoli M, Filippi I, Naldini A, Sacchetti FM, Tarantino U, Oliva F, Piccirilli E, Santoni A, Di Rosa F. GM-CSF Inhibits c-Kit and SCF

Expression by Bone Marrow-Derived Dendritic Cells. Front Immunol. 2017 Feb 16;8:147. doi: 10.3389/fimmu.2017.00147. IF:6.429

**39-** Zingoni A, Vulpis E, Nardone I, Soriani A, Fionda C, Cippitelli M, Santoni A: Targeting NKG2D and NKp30 Ligands Shedding to Improve NK Cell-Based Immunotherapy. Critical reviews in immunology 2016, 36(6):445-460. IF: 2.327

**40-** Zingoni A, Fionda C, Borrelli C, Cippitelli M, Santoni A, Soriani A. Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance. Front Immunol. 2017 Sep 25;8:1194. doi: 10.3389/fimmu.2017.01194. eCollection 2017. IF:6.429

**41-** Antonangeli F., Soriani A., Cristina C., Sciumè G., Santoni A. How mucosal epithelia deal with stress: role of NKG2D/NKG2D ligands during inflammation. Front Immunol. 2017, Front. Immunol. 1 doi: 10.3389/fimmu.2017.01583. IF:6.429

**42-** Soriani A, Stabile H, Gismondi A, Santoni A, Bernardini G. Chemokine regulation of innate lymphoid cell tissue distribution and function. Cytokine & Growth Factor Reviews. Accepted for publication. IF:6.794

Rome, 14th February 2018

Dr. Alessandra Soriani

A handwritten signature in black ink, reading "Soriani Alessandra". The signature is written in a cursive, flowing style.